Natco Pharma Announces ₹1,300 Crore Rights Issue

Natco Pharma has approved a rights issue of up to ₹1,300 crore and deferred its demerger filing with the NCLT.

Reader Takeaway: Rights issue strengthens capital base while demerger pause ensures alignment of share swap ratios for investors.

What just happened

The board of Natco Pharma has greenlit the issuance of equity shares with a face value of ₹2 each to raise up to ₹1,300 crore. A specialized Fund-Raising Committee, comprising V.C. Nannapaneni, Rajeev Nannapaneni, and P.S.R.K. Prasad, has been formed to manage the execution of this rights issue. The company will announce a record date for shareholder eligibility in due course.

Why this matters

The capital infusion is set to significantly alter the company's capital structure. Consequently, the management has opted to defer its previously announced demerger of Natco Crop Health Sciences Limited. By pausing the current NCLT filing, the company aims to recalibrate the share swap ratio to ensure the demerger remains equitable after the rights issue is finalized.

What changes now

Investors must watch for the upcoming record date announcement to confirm their eligibility for the rights offering. The demerger process will now remain in a holding pattern until the rights issue concludes, at which point the company intends to modify its scheme of arrangement and restart the formal filing process with stock exchanges and the NCLT.

Risks to watch

Investors should consider the temporary uncertainty regarding the timelines for the demerger and the potential dilution effect resulting from the issuance of new equity shares. Monitoring the finalized terms of the rights issue and the subsequent revised demerger scheme will be critical for assessing long-term value.

What to track next

Watch for the official record date for the rights issue, the finalized price per share for existing holders, and subsequent regulatory filings once the rights issue process reaches completion.